Dr. Reddy's Laboratories Limited (RDY) Company Profile & Facts

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){Le(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(eo=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Gt)),notifLabel:document.querySelector(".".concat(Wt))};to(e,n)}))}()}};

NYSE - Delayed Quote • USD

Compare

83.20 +0.67 (+0.81%)

At close: August 2 at 4:00 PM EDT

82.16 -1.04 (-1.25%)

After hours: August 2 at 6:04 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Mr. Gunupati Venkateswara Prasad B.E.	Co-Chairman, MD & Member of Management Council	2.22M	--	1960
Mr. Kallam Satish Reddy B.Tech., M.S.	Chairman of the Board & Member of the Management Council	1.39M	--	1967
Mr. Erez Israeli M.B.A.	CEO & Member of the Management Council	--	--	1968
Mr. Krishna K. Venkatesh B.Pharma M.S.	Global Head of Quality and Pharmacovigilance & Member of the Management Council	--	--	1973
Mr. Deepak Sapra M.B.A.	CEO of API & Services & Member of Management Council	--	--	1975
Mr. Venkata Ramana Motupalli M.B.A.	CEO of Branded Markets - India & Emerging Countries and Member of Management Council	--	--	1969
Ms. Archana Bhaskar B.Sc., M.B.A.	EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council	--	--	1967
Mr. Sanjay Sharma B.Tech.	Executive VP, Global Head of Global Manufacturing & Member of Management Council	--	--	1968
Mr. Patrick Aghanian B.A., M.B.A.	CEO of European Generics & Member of Management Council	--	--	1965
Mr. Mannam Venkatanarasimham	Deputy CFO & Member of the Management Council	--	--	--

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3

Banjara Hills

Hyderabad, 500034

India

91 40 4900 2900 https://www.drreddys.com

Sector:: Healthcare
Industry:
Full Time Employees:: 27,048

Description

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Corporate Governance

Dr. Reddy's Laboratories Limited’s ISS Governance QualityScore as of August 1, 2024 is 6. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.